Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Miransertib × Clear all

Phase

Status

Completed 2 Recruiting 1 No longer available 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 531 Specimen Handling 437 Carboplatin 410 Magnetic Resonance Spectroscopy 393 Cisplatin 373 Cyclophosphamide 358 Radiotherapy 331 Gemcitabine 282 Bevacizumab 274 Paclitaxel 266 Biopsy 257 Drug Therapy 251 Blood Specimen Collection 229 Nivolumab 212 venetoclax 210 Capecitabine 206 fludarabine 204 Oxaliplatin 204 Docetaxel 191 Injections 186 Fluorouracil 182 Radiosurgery 165 Dexamethasone 165 Rituximab 148 Pemetrexed 148 Standard of Care 141 Surgical Procedures, Operative 139 durvalumab 132 atezolizumab 128 tislelizumab 125

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡